Formulation of vaccines containing CpG oligonucleotides and alum.
CpG oligodeoxynucleotides are potent immunostimulants. For parenterally delivered alum-based vaccines, the immunostimulatory effect of CpG depends on the association of the CpG and antigen to the alum. We describe effects of buffer components on the binding of CPG 7909 to aluminum hydroxide (Alhydrogel), assays for measuring binding of CPG 7909 to alum and CPG 7909 induced dissociation of antigen from the alum. Free CPG 7909 is a potent inducer of IP-10 in mice. However the lack of IP-10 production from formulations containing bound CPG 7909 suggested that CPG 7909 does not rapidly dissociate from the alum after injection. It also suggests that IP-10 assays are not a good basis for potency assays for alum-based vaccines containing CPG 7909.
Aebig
Joan A
JA
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD, 20852 USA. jaebig@niaid.nih.gov <jaebig@niaid.nih.gov>
Mullen
Gregory E D
GE
Dobrescu
Gelu
G
Rausch
Kelly
K
Lambert
Lynn
L
Ajose-Popoola
Olubunmi
O
Long
Carole A
CA
Saul
Allan
A
Miles
Aaron P
AP
D000534:Alum Compounds / Q000737:chemistry; D000536:Aluminum Hydroxide / Q000737:chemistry*; D000818:Animals; D000941:Antigens / Q000737:chemistry; D002021:Buffers; D054357:Chemokine CXCL10; D019743:Chemokines, CXC / Q000097:blood; D003720:Densitometry / Q000379:methods*; D013058:Mass Spectrometry / Q000379:methods*; D051379:Mice; D009838:Oligodeoxyribonucleotides / Q000032:analysis* / Q000737:chemistry; D010710:Phosphates / Q000737:chemistry; D014612:Vaccines / Q000737:chemistry*
D000534:Alum Compounds; D000941:Antigens; D002021:Buffers; C408982:CPG-oligonucleotide; D054357:Chemokine CXCL10; D019743:Chemokines, CXC; D009838:Oligodeoxyribonucleotides; D010710:Phosphates; C483020:ProMune; D014612:Vaccines; C041524:aluminum sulfate; D000536:Aluminum Hydroxide